The Kaplan–Meier estimate and log-rank tests revealed that NHL patients with lower levels of hsa-miR-150-5p and hsa-miR-335-5p, and higher levels of MALAT1 and NEAT1 present worse OS (hsa-miR-150-5p: p = 0.019; hsas-miR-335-5p: p = 0.040; MALAT1: p = 0.020; NEAT1: p = 0.001) and worse PFS (hsa-miR-150-5p: p = 0.004; hsa-miR-335-5p: p = 0.003; MALAT1: p = 0.011; NEAT1: p = 0.003) than those with higher levels of hsa-miR-150-5p and hsa-miR-335-5p and lower levels of MALAT1 and NEAT1 (Figure 7). This evidence concerns the gene MALAT1 and non-Hodgkin lymphoma.